Literature DB >> 30947876

Hepatic Manifestations of Cystic Fibrosis.

Sasan Sakiani1, David E Kleiner2, Theo Heller3, Christopher Koh4.   

Abstract

Cystic fibrosis liver disease (CFLD) remains the third leading cause of death in patients with cystic fibrosis. Although most patients with CFLD present in childhood, recent studies suggest a second wave of liver disease in adulthood. There are no clear guidelines for diagnosing CFLD. Treatment options for CFLD remain limited, and while UDCA is widely used, its long-term benefit is unclear. Those who develop hepatic decompensation or uncontrolled variceal bleeding may benefit from liver transplant, either alone, or in combination with lung transplant. Published by Elsevier Inc.

Entities:  

Keywords:  CFLD; Cystic fibrosis liver disease; Focal biliary cirrhosis; Liver disease in cystic fibrosis; Non-cirrhotic portal hypertension

Mesh:

Substances:

Year:  2019        PMID: 30947876      PMCID: PMC6452885          DOI: 10.1016/j.cld.2018.12.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  53 in total

1.  Liver Disease in Cystic Fibrosis: Illuminating the Black Box.

Authors:  Carla Colombo; Gianfranco Alicandro
Journal:  Hepatology       Date:  2019-02-14       Impact factor: 17.425

2.  Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients.

Authors:  Cathelijne van der Feen; Hubert P J van der Doef; Cornelis K van der Ent; Roderick H J Houwen
Journal:  J Cyst Fibros       Date:  2016-11       Impact factor: 5.482

3.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

4.  Epidemiology of liver disease in cystic fibrosis: a longitudinal study.

Authors:  Thierry Lamireau; Sylvie Monnereau; Steven Martin; Jacques-Edouard Marcotte; Maria Winnock; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

5.  Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data.

Authors:  Manuel Mendizabal; K Rajender Reddy; James Cassuto; Kim M Olthoff; Thomas W Faust; George A Makar; Elizabeth B Rand; Abraham Shaked; Peter L Abt
Journal:  Liver Transpl       Date:  2011-03       Impact factor: 5.799

6.  Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis.

Authors:  J K Dowman; D Watson; S Loganathan; B K Gunson; J Hodson; D F Mirza; J Clarke; C Lloyd; D Honeybourne; J L Whitehouse; E F Nash; D Kelly; I van Mourik; P N Newsome
Journal:  Am J Transplant       Date:  2012-01-06       Impact factor: 8.086

7.  Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.

Authors:  Daniel H Leung; Mahjabeen Khan; Charles G Minard; Danielle Guffey; Louise E Ramm; Andrew D Clouston; Gregory Miller; Peter J Lewindon; Ross W Shepherd; Grant A Ramm
Journal:  Hepatology       Date:  2015-09-28       Impact factor: 17.425

Review 8.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

9.  The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Authors:  Sarah Poetter-Lang; Katharina Staufer; Pascal Baltzer; Dietmar Tamandl; Dina Muin; Nina Bastati; Emina Halilbasic; Jacqueline C Hodge; Michael Trauner; Lili Kazemi-Shirazi; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2018-07-27       Impact factor: 5.315

10.  Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.

Authors:  Pierre-Yves Boëlle; Dominique Debray; Loic Guillot; Annick Clement; Harriet Corvol
Journal:  Hepatology       Date:  2018-12-28       Impact factor: 17.425

View more
  6 in total

1.  Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study.

Authors:  Elizabeth Squirell; Joe Lockyer
Journal:  Can Liver J       Date:  2021-02-24

Review 2.  Neutrophil dysfunction in the pathogenesis of cystic fibrosis.

Authors:  Guoshun Wang; William M Nauseef
Journal:  Blood       Date:  2022-04-28       Impact factor: 25.476

3.  Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States.

Authors:  Christina Thornton; Ranjani Somayaji; Michael Parkins; Mark G Swain; Kathleen J Ramos; Christopher H Goss; Abdel A Shaheen
Journal:  Am J Gastroenterol       Date:  2021-08-01       Impact factor: 12.045

4.  Cystic fibrosis related liver disease and endocrine considerations.

Authors:  Jordan S Sherwood; Jagdeesh Ullal; Katherine Kutney; Kara S Hughan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-13

Review 5.  Cystic fibrosis associated liver disease in children.

Authors:  Joseph J Valamparampil; Girish L Gupte
Journal:  World J Hepatol       Date:  2021-11-27

6.  β-Catenin-NF-κB-CFTR interactions in cholangiocytes regulate inflammation and fibrosis during ductular reaction.

Authors:  Shikai Hu; Jacquelyn O Russell; Silvia Liu; Catherine Cao; Jackson McGaughey; Ravi Rai; Karis Kosar; Junyan Tao; Edward Hurley; Minakshi Poddar; Sucha Singh; Aaron Bell; Donghun Shin; Reben Raeman; Aatur D Singhi; Kari Nejak-Bowen; Sungjin Ko; Satdarshan P Monga
Journal:  Elife       Date:  2021-10-05       Impact factor: 8.713

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.